CND Life Sciences has opened a dedicated Innovation Laboratory in Scottsdale, Arizona, separate from its CLIA-certified clinical testing facility, to pursue assay development, biomarker research and translational work in neurodiagnostics. The company's existing Syn-One Test detects phosphorylated alpha-synuclein in cutaneous nerve fibers, with a 2024 NIH-sponsored JAMA study reporting detection in 95.5% of participants already clinically diagnosed with Parkinson's, dementia with Lewy bodies or multiple system atrophy. Accessible peripheral sampling for markers of central neurodegeneration shifts detection earlier in the disease course, where intervention remains plausible.
Key Points
- Skin nerve fibers carry detectable phosphorylated alpha-synuclein in synucleinopathies
- JAMA study: protein found in 95.5% of diagnosed patients
- Specificity in undiagnosed individuals not reported in company release
Longevity Analysis
Neurodegenerative disease is typically identified only after substantial neuronal loss, when protective strategies have limited leverage. A biopsy of accessible skin that reports on misfolded protein accumulation and peripheral nerve integrity turns an inaccessible process into a readable one, giving clinicians a signal years before motor or cognitive decline forces a diagnosis. The caveat is interpretive discipline: detection rates in people already diagnosed say nothing about false positives in the asymptomatic, and a biomarker without established specificity can mislabel a healthy individual as a patient.
Original published by Longevity.Technology, by Kyle Umipig.